The EMBO Journal (2012 Journal ( ) 31, 4486-4487. doi:10.1038 Journal ( /emboj.2012 Published online 27 November 2012 Metastasis, the process whereby tumour cells disseminate and colonize distant organs, is the primary cause of cancer mortality. Diverse models have been proposed to explain how tumour cells acquire metastatic competency. Calon et al (2012) now provide insight into the molecular underpinnings of metastasis by describing a key stromal, non-cell autonomous role for Transforming Growth Factorbeta (TGFb) in promoting the initiation of colonization in otherwise TGFb-resistant colorectal cancer (CRC) cells.
Growing tumour cells are surrounded by stroma, a heterogenous population of cells that includes fibroblasts, endothelial precursors and cells of the immune system (Sethi and Kang, 2011; Valastyan and Weinberg, 2011) . This stroma engages in an active dialogue with the tumour cells to create a unique microenvironment that is conducive to the survival and progression of a growing tumour. In late stage tumours, productive metastases arise when the tumour cells leave the primary site to disseminate throughout the body and seed new secondary tumours in distant organs. How tumour cells leave behind their primary microenvironment to establish and successfully colonize secondary sites that might harbour tumour-hostile environments has been the subject of extensive research and speculation. A recent study by Calon et al (2012) provides new insights into this long-standing question with the discovery that Transforming Growth Factor-beta (TGFb) produced by tumour cells critically promotes colorectal cancer (CRC) cell colonization through its actions on the stroma (Figure 1) .
The secreted factor, TGFb has been called the 'Dr Jekyll and Mr Hyde' of cancer (Bierie and Moses, 2006) due to paradoxical function as both a tumour suppressor and a tumour promoter. For instance, TGFb inhibits the proliferation of epithelial cells, an activity that most tumour cells must learn to overcome during cancer progression. However, TGFb also promotes the metastatic phenotype by enhancing tumour cell migration and promoting epithelialto-mesenchymal transition (EMT).
In human CRC, the majority of tumour cells display constitutive Wnt signalling, typically because of mutations in either the adenomas polyposis gene (APC) or b catenin. However, analysis of in vivo gene expression patterns revealed that it was the TBRS associated with cancerassociated fibroblasts (CAFs) that was the main predictor of poor outcome after therapy.
To provide direct evidence of a connection between stromal TGFb signalling and disease progression, Calon et al (2012) first conducted an elegant series of in vivo experiments in mice, using several colorectal cell lines that have inactivated TGFb signalling. Subcutaneous injection of variants of these lines engineered to overexpress TGFb led to activation of TGFb signalling in adjacent stroma. Calon et al (2012) next turned their attention to examining whether stromal TGFb signalling might influence metastasis. Inoculation of the engineered CRC cells in the caecum or spleen enhanced the rate of metastasis to the lung and/or liver that was particularly pronounced within the first 24 h post inoculation and most notably was abolished by administration of LY2157299, a TGFb receptor-selective inhibitor. Similarly, liver metastasis arising through intra-splenic injection of colon cancer stem cells isolated from a patient with TGFb receptor mutations was abolished by systemic TGFb receptor-inhibitor treatment. Thus, high levels of TGFb act to enhance the colonization capability of CRC cells at the initial phase of metastasis.
In breast cancer cells, which retain an intact TGFb signalling pathway, a cell-autonomous role for secreted TGFb in mediating organ-specific metastatic colonization has been delineated (Kang et al, 2003; Massague, 2008; Padua et al, 2008) . However, since the CRC cells employed by Calon et al (2012) were insensitive to TGFb, the authors focused on the question of how stromal TGFb signalling might confer a metastatic phenotype to the tumour cells. They went on to show that the IL11, which is secreted by TGFb-stimulated CAFs, acting through the GP130/STAT3 pathway in the CRC cells, was required for colonization, most likely by suppressing tumour cell apoptosis (Figure 1 ). This likely allows the tumour cells to survive in the relatively hostile metastatic environments they encounter on their way to distant sites. Indeed, CRC cells engineered to produce their own IL11 effectively colonized liver, lungs, distant lymph nodes and brain.
The process of metastasis is extremely inefficient, so how a cell might undergo the genetic and/or epigenetic changes required to leave the primary site and colonize a different organ with a distinct microenvironment is a critical question. Calon et al (2012) now provide new insights into the process by showing that TGFb signalling in CAFs directed by the tumour cells feeds back on the cancer cell in the primary site to fuel metastasis. These studies thus provide support for the notion that tumour cells acquire the necessary changes to adapt to a new environment while still residing in the primary tumour site. However, it is important to remember that the activity of TGFb on immune cells is also a potent mechanism that regulates the tumour microenvironment to promote cancer progression (Yang et al, 2010) . Although, the TBRS in CAFs was shown to be the most relevant for recurrence rates, the finding that all stromal cell types displayed TGFb-induced changes raises additional questions for future investigations that explore the extent of cellular interplay in contributing to the tumour-promoting role of TGFb. Understanding the ongoing dialogue between tumour cells and their microenvironment continues to yield a rich resource of new interventional targets that limit not only primary tumour growth, but also metastasis, the primary cause of cancer death.
